In this issue:
NIVOPOST-OP: nivolumab + cisplatin + radiotherapy in high-risk HNSCC
An injectable radio-sensitiser in frail older patients with HNSCC
ELAN-RT: hypofractionated split-course vs. standard radiotherapy in frail older patients with HNSCC
Camrelizumab + chemoradiotherapy in high-risk nasopharyngeal carcinoma
24-month progression-free status as a surrogate for OS in HPV+ oropharyngeal cancer
PaceAce: second-line paclitaxel + cetuximab in HNSCC
Osteoradionecrosis following proton therapy vs. IMRT in OPSCC
Outcomes following interruptions in (chemo) radiotherapy for HNSCC
De-escalated chemoradiotherapy using mid-treatment nodal response in low-risk p16+ OPSCC
De-escalated chemoradiotherapy using
FDG-PET in early-stage p16+ OPSCC
Please login below to download this issue (PDF)